Cycle Pharmaceuticals and Catalent Partner to Develop Treatments for Rare Diseases Using Zydis ODT Technology
31 October 2019 - 6:00PM
Business Wire
Cycle Pharmaceuticals Ltd (Cycle) is pleased to announce that it
has signed an agreement with Catalent, Inc. (Catalent) (NYSE:
CTLT), to develop innovative formulations targeting rare disease
patients. This agreement covers four products in rare metabolic and
neurological disorders and each product will utilise Catalent’s
Zydis® oral disintegrating tablet
(ODT) and Zydis Ultra®
technologies.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20191031005077/en/
Zydis® ODT Fast Dissolve Technology by
Catalent (Photo: Business Wire)
Zydis technology is recognized as one of the world’s best
performing ODTs, and has well-established advantages over
conventional oral dosage forms, including improved patient
compliance, adherence and convenience. The Zydis Ultra platform is
the company’s next generation ODT technology and allows for
increased drug load and better taste masking to be incorporated
into its proven Zydis ODT dosage form.
Commenting on the agreement, Antonio Benedetti, CEO of Cycle
said, “Cycle’s core area of expertise is to improve rare disease
medicines in order to make life easier for patients of all ages.
These drug products will benefit patients with a broad range of
unmet needs. Zydis technology has consistently proven its
effectiveness in overcoming challenges faced by patients, such as
swallowing difficulties and large pill burdens. Working in
partnership with Catalent to apply the Zydis technology to Cycle’s
product pipeline will be life-changing for both patients and their
caregivers.”
Jonathan Arnold, President of Catalent’s Oral Drug Delivery
business added, “Catalent has proven experience and expertise in
drug formulation and working with partners to bring new therapies
to market quickly. The Zydis technology platform has been shown to
be very versatile and effective in developing easy-to-administer
dose forms for innovators, and having evaluated Cycle’s molecules
at our Swindon, U.K., facility, we believe them to be excellent
candidates for further development.”
*Zydis® and Zydis Ultra® are registered trademarks of R.P.
Scherer Technologies, Inc., a wholly owned subsidiary of Catalent,
Inc. GL-0028 (October 2019)
About Cycle Pharmaceuticals
Cycle is a pioneering pharmaceutical company, reimagining how
drugs can benefit patients to make their lives easier and improve
their quality of life at every stage. Specifically, Cycle focuses
on three areas of pharmaceutical development:
- Improving orphan drugs, which treat the under-served rare
disease patient community;
- Repurposing drugs – creating a new indication for an already
existing drug; and
- Generics – reinstating generic drugs previously available in
the market
With Headquarters in Cambridge, U.K. and offices in Boston,
Mass. (USA), Cycle has developed unique partnerships with renowned
universities around the world. For further information, please
visit www.cyclepharma.com
About Catalent
Catalent (NYSE: CTLT) is the leading global provider of advanced
delivery technologies, development, and manufacturing solutions for
drugs, biologics, gene therapies, and consumer health products.
With over 85 years serving the industry, Catalent has proven
expertise in bringing more customer products to market faster,
enhancing product performance and ensuring reliable clinical and
commercial product supply. Catalent employs nearly 13,000 people,
including approximately 2,400 scientists and technicians, at more
than 35 facilities, and in fiscal year 2019 generated over $2.5
billion in annual revenue. Catalent is headquartered in Somerset
(NJ), U.S. For more information, visit www.catalent.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191031005077/en/
Name: Paula Bekinschtein Role: Head of Global Marketing Email:
info@cyclepharma.com Tel: 01223354118
Catalent (NYSE:CTLT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Catalent (NYSE:CTLT)
Historical Stock Chart
From Oct 2023 to Oct 2024